Meptyldinocap

Synonyms: 敌螨普; 2,4-DNOPC
Meptyldinocap (2,4-DNOPC) 是一种可作用于白粉病的杀真菌剂与细胞毒性剂,能上调 ERK1/2、JNK 和 p38 的磷酸化水平,诱导细胞凋亡 (apoptosis) 和内质网应激并破坏钙稳态,抑制细胞增殖与迁移,下调增殖及妊娠相关基因的表达,引发线粒体功能障碍,可用于白粉病和着床失败相关研究。
产品编号: MS-Y02014 纯度: 99.91% CAS No.: 131-72-6 分子式: C18H24N2O6 分子量: 364.39
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
10mM * 1mL in DMSO
询价
3-5 天
5mg
询价
3-5 天
10mg
询价
3-5 天
25mg
询价
3-5 天
50mg
询价
3-5 天
100mg
询价
询价
200mg
询价
询价

产品描述

Meptyldinocap (2,4-DNOPC) 是一种可作用于白粉病的杀真菌剂与细胞毒性剂,能上调 ERK1/2、JNK 和 p38 的磷酸化水平,诱导细胞凋亡 (apoptosis) 和内质网应激并破坏钙稳态,抑制细胞增殖与迁移,下调增殖及妊娠相关基因的表达,引发线粒体功能障碍,可用于白粉病和着床失败相关研究。

生物实验数据

生物活性 Meptyldinocap (2,4-DNOPC) is a fungicide and cytotoxic agent that acts on powdery mildew, upregulates the phosphorylation levels of ERK1/2, JNK, and p38, induces apoptosis and endoplasmic reticulum stress and disrupts calcium homeostasis, inhibits cell proliferation and migration, downregulates the expression of proliferation- and pregnancy-related genes, triggers mitochondrial dysfunction, and can be used in research related to powdery mildew and implantation failure.
体外研究
(In Vitro)

Meptyldinocap (10-500 nM; 48 h) 可呈浓度依赖性降低 pTr 和 pLE 细胞的活力。
Meptyldinocap (150 nM; 48 h) 可降低 pTr 和 pLE 细胞中增殖相关基因 PCNA 与 CDK1 的表达水平。
Meptyldinocap (150 nM; 24 h) 可降低 pTr 和 pLE 细胞中增殖标志物 PCNA 与 Ki67 的蛋白表达水平。
Meptyldinocap (50-150 nM; 48 h) 可提高 pTr 细胞早期和晚期凋亡的比例;处理 48 h 后,150 nM 浓度可提高 pLE 细胞早期凋亡的比例,而 100 和 150 nM 浓度可提高 pLE 细胞晚期凋亡的比例。
Meptyldinocap (50-150 nM; 48 h) 可在 pTr 细胞中诱导浓度依赖性的细胞周期阻滞。
Meptyldinocap (150 nM; 24 h) 可显著降低 pTr 细胞的线粒体最大呼吸水平;处理 24 h 后,其在 pLE 细胞中呈现出线粒体呼吸参数降低的非显著性趋势。
Meptyldinocap (150 nM; 48 h) 处理 48 h 后可导致 pTr 细胞和 pLE 细胞的线粒体膜电位 (MMP) 显著下降至 207.5% 和 271.1%。
Meptyldinocap (50-150 nM; 48 h) 可上调 pTr 细胞中内质网应激相关蛋白 GRP78 和 p-eIF2α 的表达。
Meptyldinocap (50-150 nM; 48 h) 可降低 pTr 细胞和 pLE 细胞的胞质钙浓度,从而破坏钙稳态。
Meptyldinocap (50-150 nM; 30 min) 可上调 pTr 细胞中 ERK1/2、JNK 和 p38 的磷酸化水平,从而改变 MAPK 信号级联反应。

Cell Viability Assay

Cell Line: porcine trophectoderm (pTr) cells, porcine endometrial luminal (pLE) cells
Concentration: 10, 20, 50, 100, 200, 500 nM
Incubation Time: 48 h
Result: Decreased cell viability significantly at 100, 200, and 500 nM in both cell lines.
Reduced cell viability to 50% between 100 and 200 nM for both cell lines.

Real Time qPCR

Cell Line: porcine trophectoderm (pTr) cells, porcine endometrial luminal (pLE) cells
Concentration: 150 nM
Incubation Time: 48 h
Result: Reduced PCNA expression to 0.31-fold lower in pTr cells and 0.20-fold lower in pLE cells compared to vehicle-treated controls.
Reduced CDK1 expression to 0.11-fold lower in both cell types compared to vehicle-treated controls.

Immunofluorescence

Cell Line: porcine trophectoderm (pTr) cells, porcine endometrial luminal (pLE) cells
Concentration: 150 nM
Incubation Time: 24 h
Result: Reduced PCNA expression in both cell lines.
Reduced the signal intensity of Ki67 in pTr and pLE cells.

Apoptosis Analysis

Cell Line: porcine trophectoderm (pTr) cells, porcine endometrial luminal (pLE) cells
Concentration: 50, 100, 150 nM
Incubation Time: 48 h
Result: Increased early apoptotic pTr cells to 294.1%, 310.8%, and 310.8% across 50, 100, 150 nM respectively.
Increased late apoptotic pTr cells to 156.6%, 220.9%, and 225.3% across 50, 100, 150 nM respectively.
Showed non-significant increases in early apoptotic pLE cells at 50 and 100 nM, and a significant increase to 310.8% at 150 nM.
Showed non-significant increase in late apoptotic pLE cells at 50 nM, significant increases at 100 nM and 150 nM (225.3%).

Cell Cycle Analysis

Cell Line: porcine trophectoderm (pTr) cells, porcine endometrial luminal (pLE) cells
Concentration: 50, 100, 150 nM
Incubation Time: 48 h
Result: Induced G1-arrest in pTr cells at 50 nM (G1-phase proportion increased to 80.9%) and 100 nM (G1-phase proportion increased to 84.7%), and G2-arrest at 150 nM (G2-phase proportion increased to 25.4%).
Decreased S-phase cell proportion significantly in pTr cells at 50 and 100 nM.
Induced G1-arrest in pLE cells at all tested concentrations (G1-phase proportion increased to 75.1%, 77.9%, and 77.2% respectively), with significant decreases in S-phase cells at all concentrations.
Reduced CCNB1 expression in pTr cells to 0.73-fold, 0.14-fold, 0.08-fold lower at 50, 100, 150 nM respectively; reduced CCNB1 expression in pLE cells to 0.40-fold and 0.12-fold lower at 100 and 150 nM respectively (no significant change at 50 nM).
Reduced CCND1 expression in pTr cells to 0.76-fold, 0.73-fold, 0.90-fold lower at 50, 100, 150 nM respectively; showed no significant alteration in CCND1 expression in pLE cells.

Western Blot Analysis

Cell Line: porcine trophectoderm (pTr) cells, porcine endometrial luminal (pLE) cells
Concentration: 50, 100, 150 nM
Incubation Time: 48 h
Result: Upregulated GRP78 expression to 233.8%, 348.2%, and 678.4% at 50, 100, 150 nM respectively in pTr cells.
Upregulated p-eIF2α expression to 189.5%, 198.0%, and 214.2% at 50, 100, 150 nM respectively in pTr cells.
Upregulated GRP78 expression to 199.9% at 150 nM in pLE cells.
Upregulated p-eIF2α expression to 165.7%, 199.8%, and 230.9% at 50, 100, 150 nM respectively in pLE cells.

Western Blot Analysis

Cell Line: porcine trophectoderm (pTr) cells, porcine endometrial luminal (pLE) cells
Concentration: 50, 100, 150 nM
Incubation Time: 30 min
Result: Upregulated phospho-ERK1/2 levels to 125.5%, 139.8%, and 149.8% at 50, 100, 150 nM respectively in pTr cells.
Upregulated phospho-JNK levels to 130.4%, 135.9%, and 149.8% at 50, 100, 150 nM respectively in pTr cells.
Upregulated phospho-p38 levels to 124.5%, 150.9%, and 159.8% at 50, 100, 150 nM respectively in pTr cells.
Upregulated phospho-ERK1/2 levels to 159.4% and 175.0% at 100 and 150 nM respectively in pLE cells.
Upregulated phospho-JNK levels to 156.6% and 151.8% at 100 and 150 nM respectively in pLE cells.
Upregulated phospho-p38 levels to 181.7%, 163.5%, and 171.1% at 50, 100, 150 nM respectively in pLE cells.
性状 油状物
颜色 Light yellow to yellow

化学信息

分子量 364.39
分子式 C18H24N2O6
CAS No. 131-72-6
别名 敌螨普; 2,4-DNOPC

储存&溶解度

体内实验配方
10% DMSO+40% PEG300+5% Tween 80+45% Saline: 4 mg/mL (10.98 mM), Sonication is recommended.
请按顺序添加溶剂,在添加下一种溶剂之前,尽可能使溶液澄清。如有必要,可通过加热、超声、涡旋处理进行溶解。工作液建议现配现用。以上配方仅供参考,体内配方并不是绝对的,请根据不同情况进行调整。
储存方式
Pure form -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

DMSO 中的溶解度 : ≥ 150 mg/mL (411.65 mM; 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

Ethanol 中的溶解度 : 100 mg/mL (274.43 mM; 超声助溶)

* "≥" means soluble, but saturation unknown.

可选溶剂浓度1 mg5 mg10 mg25 mg
Ethanol / DMSO1 mM2.7443 mL13.7216 mL27.4431 mL68.6078 mL
5 mM0.5489 mL2.7443 mL5.4886 mL13.7216 mL
10 mM0.2744 mL1.3722 mL2.7443 mL6.8608 mL
15 mM0.1830 mL0.9148 mL1.8295 mL4.5739 mL
20 mM0.1372 mL0.6861 mL1.3722 mL3.4304 mL
25 mM0.1098 mL0.5489 mL1.0977 mL2.7443 mL
30 mM0.0915 mL0.4574 mL0.9148 mL2.2869 mL
40 mM0.0686 mL0.3430 mL0.6861 mL1.7152 mL
50 mM0.0549 mL0.2744 mL0.5489 mL1.3722 mL
60 mM0.0457 mL0.2287 mL0.4574 mL1.1435 mL
80 mM0.0343 mL0.1715 mL0.3430 mL0.8576 mL
100 mM0.0274 mL0.1372 mL0.2744 mL0.6861 mL

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础